|3.01||-0.0200||-0.66%||Vol 250.23K||1Y Perf -|
|Oct 4th, 2023 16:00 DELAYED|
|- -||-0.01 -0.33%|
|Target Price||9.00||Analyst Rating||Hold 3.17|
|Potential %||199.00||Finscreener Ranking||★★★★★ 65.52|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★★★★★ 71.24|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||★★★★★ 78.12|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||3.78||Earnings Rating||Strong Buy|
|Market Cap||251.03M||Earnings Date||6th Nov 2023|
Today's Price Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||6th Nov 2023|
|Estimated EPS Next Report||-0.46|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||168.98K|
|Avg. Monthly Volume||310.98K|
|Avg. Quarterly Volume||469.12K|
Aviragen Therapeutics, Inc. (NASDAQ: AVIR) stock closed at 7.08 per share at the end of the most recent trading day (a 0.83% change compared to the prior day closing price) with a volume of 488.04K shares and market capitalization of 251.03M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drugs - Generic industry, Healthcare sector and employs people. Aviragen Therapeutics, Inc. CEO is .
The one-year performance of Aviragen Therapeutics, Inc. stock is %, while year-to-date (YTD) performance is -57.2%. AVIR stock has a five-year performance of 269.51%. Its 52-week range is between 2.88 and 6.32, which gives AVIR stock a 52-week price range ratio of 3.78%
Aviragen Therapeutics, Inc. currently has a PE ratio of 14.20, a price-to-book (PB) ratio of 0.59, a price-to-sale (PS) ratio of 1.99, a price to cashflow ratio of 1.80, a PEG ratio of -, a ROA of 4.66%, a ROC of 4.81% and a ROE of 5.73%. The company’s profit margin is 18.55%, its EBITDA margin is 15.90%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Aviragen Therapeutics, Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.46 for the next earnings report. Aviragen Therapeutics, Inc.’s next earnings report date is 06th Nov 2023.
The consensus rating of Wall Street analysts for Aviragen Therapeutics, Inc. is Hold (3.17), with a target price of $9, which is +199.00% compared to the current price. The earnings rating for Aviragen Therapeutics, Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aviragen Therapeutics, Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aviragen Therapeutics, Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 23.09, ATR14 : 0.36, CCI20 : 81.22, Chaikin Money Flow : 0.15, MACD : 0.00, Money Flow Index : 73.90, ROC : 28.73, RSI : 0.00, STOCH (14,3) : 80.19, STOCH RSI : 0.00, UO : 54.11, Williams %R : -19.81), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aviragen Therapeutics, Inc. in the last 12-months were: Franklin M. Berger (Sold 41 666 shares of value $214 685 )
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.